IL215593A0 - Compositions for immunising against staphylococcus aureus - Google Patents

Compositions for immunising against staphylococcus aureus

Info

Publication number
IL215593A0
IL215593A0 IL215593A IL21559311A IL215593A0 IL 215593 A0 IL215593 A0 IL 215593A0 IL 215593 A IL215593 A IL 215593A IL 21559311 A IL21559311 A IL 21559311A IL 215593 A0 IL215593 A0 IL 215593A0
Authority
IL
Israel
Prior art keywords
compositions
staphylococcus aureus
against staphylococcus
immunising against
immunising
Prior art date
Application number
IL215593A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42734088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL215593(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL215593A0 publication Critical patent/IL215593A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL215593A 2009-04-14 2011-10-06 Compositions for immunising against staphylococcus aureus IL215593A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21270509P 2009-04-14 2009-04-14
US23407909P 2009-08-14 2009-08-14
PCT/IB2010/000998 WO2010119343A2 (en) 2009-04-14 2010-04-14 Compositions for immunising against staphylococcus aureus

Publications (1)

Publication Number Publication Date
IL215593A0 true IL215593A0 (en) 2011-12-29

Family

ID=42734088

Family Applications (1)

Application Number Title Priority Date Filing Date
IL215593A IL215593A0 (en) 2009-04-14 2011-10-06 Compositions for immunising against staphylococcus aureus

Country Status (24)

Country Link
US (5) US8679505B2 (ja)
EP (3) EP2510947B1 (ja)
JP (5) JP5830009B2 (ja)
KR (1) KR20120034612A (ja)
CN (2) CN102647999A (ja)
AU (1) AU2010238255B2 (ja)
BR (1) BRPI1013780B8 (ja)
CA (2) CA2758490C (ja)
CO (1) CO6440592A2 (ja)
DK (1) DK2510947T3 (ja)
ES (1) ES2565377T3 (ja)
HR (1) HRP20160276T1 (ja)
HU (1) HUE028803T2 (ja)
IL (1) IL215593A0 (ja)
MX (3) MX363222B (ja)
NZ (2) NZ612315A (ja)
PH (1) PH12015500092A1 (ja)
PL (1) PL2510947T3 (ja)
RU (2) RU2508126C2 (ja)
SG (2) SG175092A1 (ja)
SI (1) SI2510947T1 (ja)
SM (1) SMT201600117B (ja)
WO (1) WO2010119343A2 (ja)
ZA (1) ZA201302878B (ja)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007536644A (ja) * 2004-05-06 2007-12-13 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 画像を整列させ分類するための方法およびシステム
EP2368569A3 (en) * 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
MX363222B (es) 2009-04-14 2019-03-15 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago PROTEIN A (SPA) ANTIBODY COMPOSITIONS AND METHODS AS AN IMMUNE RESPONSE AMPLIFIER
PL3444268T3 (pl) * 2010-05-05 2022-04-19 New York University Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
CA2804492A1 (en) 2010-07-06 2012-01-12 Novartis Ag Immunisation of large mammals with low doses of rna
US11291635B2 (en) 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
PT4066856T (pt) 2010-08-31 2023-01-02 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
BR112013005134A2 (pt) 2010-09-01 2018-04-24 Novartis Ag adsorção de imunopotenciadores em sais metálicos insolúveis
US9095540B2 (en) 2010-09-09 2015-08-04 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
CN103269713B (zh) 2010-10-11 2016-01-20 诺华有限公司 抗原递送平台
WO2012082914A1 (en) 2010-12-14 2012-06-21 Novartis Ag Flow cytometry analysis of materials adsorbed to metal salts
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
EP2694534B1 (en) * 2011-04-08 2018-06-20 Evaxion Biotech ApS Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
EP3777885A1 (en) 2011-06-19 2021-02-17 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
US8846609B2 (en) 2011-06-19 2014-09-30 New York University Leukotoxin E/D as a new anti-inflammatory agent and microbicide
EP2729126B1 (en) 2011-07-06 2020-12-23 GlaxoSmithKline Biologicals SA Liposomes having useful n:p ratio for delivery of rna molecules
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
FR2977800B1 (fr) * 2011-07-13 2014-03-14 Sanofi Pasteur Composition vaccinale avec des nanoparticules d'hydroxyde d'aluminium
AU2012301715B2 (en) 2011-08-31 2017-08-24 Glaxosmithkline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding RNA
AU2012300765A1 (en) * 2011-09-01 2014-03-13 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
US20150044251A1 (en) * 2011-12-23 2015-02-12 Novartis Ag Stable compositions for immunising against staphylococcus aureus
JP6325986B2 (ja) 2012-03-07 2018-05-16 ノバルティス アーゲー 免疫学的に有用なアルギニン塩
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
CN104159602B (zh) 2012-03-08 2017-10-24 葛兰素史密丝克莱恩生物有限公司 加强疫苗的含佐剂制剂
EP3805395A1 (en) * 2012-04-26 2021-04-14 University Of Chicago Staphylococcal coagulase antigens and methods of their use
WO2014011645A1 (en) * 2012-07-10 2014-01-16 Merck Sharp & Dohme Corp. Protective vaccine based on staphylococcus aureus sa2493 protein
CN104684570A (zh) * 2012-08-31 2015-06-03 诺华股份有限公司 用于免疫抵抗金黄色葡萄球菌的稳定化的蛋白质
US20150203543A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
CN110563818A (zh) * 2012-08-31 2019-12-13 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
WO2014033192A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
CA2882382A1 (en) 2012-09-18 2014-03-27 Novartis Ag Outer membrane vesicles
CN102993308B (zh) * 2012-09-29 2014-11-05 重庆原伦生物科技有限公司 耐甲氧西林金黄色葡萄球菌（mrsa）疫苗重组蛋白抗原hi2及制备方法和应用
GB201217868D0 (en) * 2012-10-05 2012-11-21 Isis Innovation Staphyolococcus aureus antigens
CN105164102B (zh) 2013-03-08 2017-12-15 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
EP3441474B1 (en) * 2013-06-18 2020-07-22 New York University Pharmaceutical compositions containing a mutated leukocidin e
US20160368952A1 (en) * 2013-12-03 2016-12-22 Evaxion Biotech Aps Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
ES2754209T3 (es) 2013-12-13 2020-04-16 Stora Enso Oyj Cartón multicapa
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2015140108A1 (en) * 2014-03-17 2015-09-24 Gaxosmithkline Biologicals Sa Immunising against staphylococcal bone and joint infections
CN106103469B (zh) * 2014-03-26 2020-11-27 葛兰素史密丝克莱恩生物有限公司 突变型葡萄球菌抗原
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
WO2015162100A1 (en) * 2014-04-21 2015-10-29 Novartis Ag Vaccine adjuvants
EP3169309B1 (en) 2014-07-16 2023-05-10 Novartis AG Method of encapsulating a nucleic acid in a lipid nanoparticle host
WO2016037053A1 (en) 2014-09-05 2016-03-10 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2016095832A1 (en) * 2014-12-18 2016-06-23 The University Of Hong Kong Immunotherapeutic targets against staphylococcus aureus
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
EP3302532A4 (en) 2015-06-05 2019-01-09 New York University COMPOSITIONS AND METHODS RELATED TO ANTISTAPHYLOCOCCAL BIOLOGICAL AGENTS
CA3000561C (en) * 2015-09-24 2022-03-22 F. Hoffman-La Roche Ag Alpha-hemolysin variants
EP3362089B1 (en) 2015-10-13 2023-12-06 Sanofi Pasteur Immunogenic compositions against s. aureus
AU2017218768B2 (en) * 2016-02-12 2022-03-31 Janssen Pharmaceuticals, Inc. Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
SG10201912431XA (en) * 2016-10-21 2020-02-27 Socpra Sciences Et Genie Sec Vaccine constructs and uses thereof against staphylococcus infections
CN107224576A (zh) * 2017-03-06 2017-10-03 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位的疫苗及其制备方法和应用
CA3061709A1 (en) * 2017-03-28 2018-10-04 The Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
CN107827961B (zh) * 2017-10-11 2020-05-26 深圳市南山区人民医院 用于金黄色葡萄球菌Staphopain B蛋白检测的B细胞抗原表位肽及其试剂盒
GB201721576D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
EP3768704A1 (en) * 2018-03-21 2021-01-27 Doderm GmbH Treatment of staphylococcus related diseases
KR102205620B1 (ko) 2019-05-16 2021-01-21 한국과학기술연구원 혈중 내 극소량 존재하는 miRNA의 검출 효율의 증가 방법
CN110256556A (zh) * 2019-06-28 2019-09-20 成都欧林生物科技股份有限公司 一种耐甲氧西林金黄色葡萄球菌人免疫球蛋白及制备方法
KR20220124194A (ko) * 2019-12-31 2022-09-13 앙타고니 에스. 아우레우스 감염을 예방하기 위한 조성물 및 방법
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112851770B (zh) * 2021-02-05 2022-10-04 中国人民解放军陆军军医大学 一种用于诊断或防治金黄色葡萄球菌感染的α溶血素抗原表位肽及其应用
EP4387596A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Low-dose lyophilized rna vaccines and methods for preparing and using the same
EP4387597A1 (en) 2021-08-16 2024-06-26 GlaxoSmithKline Biologicals SA Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
CN116179663B (zh) * 2023-01-30 2023-12-22 天津大学 一种基于γ-溶血素纳米孔道收缩区实现核酸单分子片段式测序的方法

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
NZ241926A (en) 1988-08-25 1993-08-26 Liposome Co Inc Immunisation dosage form comprising a salt of an organic acid derivative of a sterol and an antigen
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0465529B1 (en) 1989-03-21 1998-04-29 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
DE69132031T2 (de) 1990-12-20 2000-07-13 Arch Development Corp., The University Of Chicago Kontrolle der genexpression durch ionisierende strahlung
SG70625A1 (en) 1991-03-01 2000-02-22 Minnesota Mining & Mfg 1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
KR100341341B1 (ko) 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0711829A3 (en) 1993-09-15 1997-07-09 Viagene Inc Recombinant alphavirus vector
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
HUT75162A (en) 1993-11-16 1997-04-28 Depotech Corp Vesicles with controlled release of actives
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
CA2283557A1 (en) 1997-03-10 1998-09-17 Heather L. Davis Use of nucleic acids containing unmethylated cpg dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
AU8586298A (en) 1997-07-25 1999-02-16 University Of Massachusetts Designed protein pores as components for biosensors
EP0905243A2 (en) * 1997-08-05 1999-03-31 Smithkline Beecham Corporation Polynucleotides from Staphylococcus aureus expressed in infected tissue
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
KR100585408B1 (ko) 1998-02-12 2006-06-01 와이어쓰 홀딩스 코포레이션 인터루킨-12로 제형된 폐렴구균 및 수막구균 백신
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
TR200002930T2 (tr) 1998-04-09 2000-12-21 Smithkline Beecham Biologicals S.A. Kolaylaştırıcı kompozisyonlar
DK1075276T3 (da) 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
JP2004505885A (ja) 1998-08-19 2004-02-26 ノース　アメリカン　ワクチン，　インコーポレイテッド Ｎ−アクリロイル化ポリサッカリドを用いて産生されたワクチンとして有用な免疫原性β−プロピオンアミド連結ポリサッカリド−タンパク質結合体
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
ATE276199T1 (de) 1999-02-03 2004-10-15 Biosante Pharmaceuticals Inc Methoden zur herstellung von therapeutische kalzium-phosphat partikeln
ES2300255T3 (es) 1999-03-19 2008-06-16 Glaxosmithkline Biologicals S.A. Vacunas contra antigenos de bacterias.
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1221971A2 (en) 1999-09-24 2002-07-17 SmithKline Beecham Biologics SA Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
AP1775A (en) 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2001293233A1 (en) 2000-09-01 2002-03-13 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
DK1317442T3 (da) 2000-09-11 2006-02-13 Chiron Corp Quinolinonderivater som tyrosinkinaseinhibitorer
AU2001294750C1 (en) 2000-09-26 2008-09-18 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA75622C2 (en) 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
WO2003020875A2 (en) * 2001-06-17 2003-03-13 D-Squared Biotechnologies, Inc. Staphylococci surface-exposed immunogenic polypeptides
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6924271B2 (en) 2001-11-27 2005-08-02 Anadys Pharmaceuticals, Inc. 3-β-D-ribofuranosylthiazolo[4-5-d]pyridimine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1499311B1 (en) 2002-03-29 2009-11-04 Novartis Vaccines and Diagnostics, Inc. Substituted benzazoles and use thereof as raf kinase inhibitors
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
CN1688573A (zh) 2002-08-23 2005-10-26 希龙公司 糖原合成酶激酶3的吡咯基抑制剂
EP1587473A4 (en) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
DE602004025579D1 (de) 2003-07-24 2010-04-01 Merck & Co Inc Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
WO2005009378A2 (en) 2003-07-24 2005-02-03 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
AU2005214061B2 (en) 2004-02-18 2010-02-04 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
US20070172498A1 (en) 2004-02-27 2007-07-26 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphyloococcus aureus
CA2560969A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
EP1742659B1 (en) 2004-04-05 2013-03-13 Pah Usa 15 Llc Microfluidized oil-in-water emulsions and vaccine compositions
EP1753441A2 (en) 2004-05-25 2007-02-21 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
AU2005287145A1 (en) 2004-09-17 2006-03-30 Merck & Co., Inc. Polypeptides for inducing a protective immune response against Staphylococcus aureus
GB0421079D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Immunogenic composition
WO2007001423A2 (en) * 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
WO2006078680A2 (en) 2005-01-21 2006-07-27 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
DK2878307T3 (da) 2005-06-27 2019-10-07 Glaxosmithkline Biologicals Sa Immunogen sammensætning
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
EP2368569A3 (en) * 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
MY148405A (en) 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
AR060188A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
MX2008015814A (es) 2006-06-12 2009-01-12 Nabi Biopharmaceuticals Uso de alfa-toxina para tratar y prevenir infecciones por staphylococcus.
DK2086582T3 (da) 2006-10-12 2013-02-04 Glaxosmithkline Biolog Sa Vaccine omfattende en olie-i-vand-emulsionsadjuvans
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
CA2687681A1 (en) 2007-05-31 2009-03-05 Merck & Co., Inc. Antigen-binding proteins targeting s. aureus orf0657n
EP2185190B1 (en) * 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
EP2344189B1 (en) 2008-09-30 2018-05-30 University of Maryland, Baltimore Protective vaccine against staphylococcus aureus biofilms comprising cell wall-associated immunogens
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
MX363222B (es) * 2009-04-14 2019-03-15 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.

Also Published As

Publication number Publication date
US20120107340A1 (en) 2012-05-03
CN102647999A (zh) 2012-08-22
US8679505B2 (en) 2014-03-25
HRP20160276T1 (hr) 2016-04-08
PL2510947T3 (pl) 2016-09-30
WO2010119343A2 (en) 2010-10-21
CA3154626A1 (en) 2010-10-21
US9642904B2 (en) 2017-05-09
BRPI1013780A2 (pt) 2019-07-02
ES2565377T3 (es) 2016-04-04
AU2010238255A1 (en) 2011-11-03
CO6440592A2 (es) 2012-05-15
DK2510947T3 (en) 2016-03-21
CA2758490A1 (en) 2010-10-21
PH12015500092A1 (en) 2015-12-02
RU2011146016A (ru) 2013-05-20
WO2010119343A3 (en) 2011-04-07
SMT201600117B (it) 2016-07-01
KR20120034612A (ko) 2012-04-12
JP2022078317A (ja) 2022-05-24
MX363222B (es) 2019-03-15
US8632783B2 (en) 2014-01-21
JP2020007351A (ja) 2020-01-16
US10195263B2 (en) 2019-02-05
RU2508126C2 (ru) 2014-02-27
AU2010238255B2 (en) 2014-10-16
BRPI1013780B8 (pt) 2022-10-04
US20120093850A1 (en) 2012-04-19
WO2010119343A8 (en) 2012-04-26
SG10201404076TA (en) 2014-10-30
SI2510947T1 (sl) 2016-05-31
JP2016020390A (ja) 2016-02-04
CN109248313B (zh) 2023-01-17
EP2510947A1 (en) 2012-10-17
EP2419129A2 (en) 2012-02-22
NZ612315A (en) 2014-10-31
US20170340720A1 (en) 2017-11-30
EP3263128A3 (en) 2018-01-24
ZA201302878B (en) 2013-12-23
CN109248313A (zh) 2019-01-22
US9205142B2 (en) 2015-12-08
BRPI1013780B1 (pt) 2021-09-14
NZ595689A (en) 2014-03-28
RU2013154779A (ru) 2015-06-20
SG175092A1 (en) 2011-11-28
US20160158335A1 (en) 2016-06-09
JP2017193574A (ja) 2017-10-26
JP5830009B2 (ja) 2015-12-09
EP3263128A2 (en) 2018-01-03
MX2011010735A (es) 2012-01-25
CA2758490C (en) 2023-05-02
US20140178425A1 (en) 2014-06-26
MX2019003004A (es) 2019-08-05
JP2012523246A (ja) 2012-10-04
HUE028803T2 (en) 2017-01-30
JP7109412B2 (ja) 2022-07-29
EP2510947B1 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
IL215593A0 (en) Compositions for immunising against staphylococcus aureus
IL257693B (en) Fungicides
HK1246216B (zh) 抗微生物組合物
GB2473460B (en) Antimicrobial Composition
EP2549993A4 (en) ANTIMICROBIAL COMPOSITIONS
HK1157665A1 (zh) 抗微生物組合物
ZA201301479B (en) Fungicidal compositions
HK1213821A1 (zh) 抗微生物組合物
PL2458993T3 (pl) Synergistyczna kompozycja przeciwdrobnoustrojowa
PL2461693T3 (pl) Synergistyczna kompozycja biobójcza
PL2461692T3 (pl) Synergistyczna kompozycja biobójcza
GB2472315B (en) Antibacterial compositions
GB0909030D0 (en) Antibacterial composition
GB0920891D0 (en) Herbicidal compositions
EP2605654A4 (en) ANTIMICROBIAL COMPOSITIONS
GB0903955D0 (en) Fungicidal compositions
PL2681998T3 (pl) Synergistyczna kompozycja biobójcza
GB0919690D0 (en) compositions for immunising against staphylococcus aureus
EP2467018A4 (en) PHYTOCEUTICAL COMPOSITIONS FOR PETS
GB0910411D0 (en) Antibacterial compositions
GB201111128D0 (en) Antimicrobial compositions
GB201013150D0 (en) Antimicrobial compositions
GB201010944D0 (en) Antimicrobial compositions
GB201003799D0 (en) Antimicrobial compositions
GB201002594D0 (en) Antimicrobial compositions